TY -的T1 -促红细胞生成素对亿旺资讯公司的影响ed pulmonary vascular remodelling JF - European Respiratory Journal JO - Eur Respir J SP - 126 LP - 134 DO - 10.1183/09031936.00035607 VL - 31 IS - 1 AU - van Albada, M. E. AU - du Marchie Sarvaas, G. J. AU - Koster, J. AU - Houwertjes, M. C. AU - Berger, R. M. F. AU - Schoemaker, R. G. Y1 - 2008/01/01 UR - //www.qdcxjkg.com/content/31/1/126.abstract N2 - Erythropoietin (EPO) mobilises endothelial progenitor cells and promotes neovascularisation in heart failure. The present authors studied the effects of EPO on pulmonary vascular and cardiac remodelling in a model for flow-associated pulmonary arterial hypertension (PAH). PAH was induced in adult male Wistar rats by the injection of monocrotaline combined with an abdominal aortocaval shunt 1 week later (PAH or experimental group). Immediately afterwards, rats were randomised into those who received treatment with EPO (PAH+EPO group) and controls. Pulmonary and systemic haemodynamics, and right ventricular and pulmonary vascular remodelling were evaluated 3 weeks later. Vascular occlusion of the intra-acinar pulmonary vessels (13.4±0.7 versus 16.7±1.3% in PAH+EPO and PAH, respectively) and medial wall thickness of the pre-acinar arteries (wall-to-lumen ratio 0.13±0.01 versus 0.17±0.01 in PAH+EPO and PAH, respectively) decreased after treatment with EPO. Moreover, right ventricular capillary density was increased by therapy (2,322±61 versus 2,100±63 capillaries·mm−2 in PAH+EPO and PAH, respectively). Increased mean pulmonary arterial pressure and decreased right ventricular contractility in the model were not altered by EPO treatment. In this rat model of flow-associated pulmonary arterial hypertension, erythropoietin treatment beneficially affected pulmonary vascular and cardiac remodelling. These histopathological effects were not accompanied by significantly improved haemodynamics. ER -